Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Niagen Bioscience ( (NAGE) ).
On October 6, 2025, Niagen Bioscience announced an increase in its full-year 2025 net sales outlook to 25% to 30% year-over-year growth, up from the previous forecast of 22% to 27%. This adjustment reflects the company’s confidence in its market position, particularly following the FDA’s reversal of rulings on the DSHEA drug preclusion rule related to NMN, which could enhance awareness of the NAD+ precursor market. Niagen Bioscience emphasizes the superiority of its Niagen product over NMN supplements, citing issues with NMN products infringing on its patent portfolio and failing to meet label claims. The company’s robust IP protection and focus on quality and efficacy position it strongly in the growing NAD+ supplementation market.
The most recent analyst rating on (NAGE) stock is a Hold with a $8.50 price target. To see the full list of analyst forecasts on Niagen Bioscience stock, see the NAGE Stock Forecast page.
Spark’s Take on NAGE Stock
According to Spark, TipRanks’ AI Analyst, NAGE is a Neutral.
Niagen Bioscience’s strong financial performance is a key strength, driven by improved profitability and cash flow. However, technical indicators suggest bearish momentum, and the stock’s valuation is moderate with no dividend yield. The absence of earnings call data and corporate events limits further insights.
To see Spark’s full report on NAGE stock, click here.
More about Niagen Bioscience
Niagen Bioscience, Inc., formerly ChromaDex Corp., is a leading company in the NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research industry. The company focuses on advancing healthspan through precision science and innovative NAD+-boosting solutions. Niagen Bioscience is renowned for its state-of-the-art laboratories, rigorous scientific protocols, and collaborations with leading research institutions. Its flagship product, Niagen® (patented nicotinamide riboside, NR), is a highly efficient NAD+ booster, powering consumer supplements like Tru Niagen® and Niagen Plus™.
Average Trading Volume: 1,116,661
Technical Sentiment Signal: Buy
Current Market Cap: $552.7M
Learn more about NAGE stock on TipRanks’ Stock Analysis page.